Neurology, Musculoskeletal Health
Targeting Unmet Needs in the Treatment of Focal Spasticity Patient Health Management (PHM) Program
Duration: 1.0 hr | # of Credits: 0 | Accreditation: Unaccredited | Sponsor: Ipsen Biopharmaceuticals Canada Inc. New interactive educational program to help clinicians manage complex spasticity in persons receiving botulinum toxin-A (BoNT-A) treatment. Unaccredited 30-minute CME course: The goal of this course is to assist clinicians in the management of complex spasticity in persons receiving […]
DURATION
1 hour
PROFESSION
Specialist
# OF CREDITS
0
ACCREDITATION
EXPIRY DATE
2023-05-05
Duration: 1.0 hr | # of Credits: 0 | Accreditation: Unaccredited | Sponsor: Ipsen Biopharmaceuticals Canada Inc.
New interactive educational program to help clinicians manage complex spasticity in persons receiving botulinum toxin-A (BoNT-A) treatment.
Unaccredited 30-minute CME course:
The goal of this course is to assist clinicians in the management of complex spasticity in persons receiving botulinum toxin-A (BoNT-A) treatments. This includes multi-modal treatment approaches to address symptoms that recur between BoNT-A injection.
Patient assessment tool:
Complete this assessment for 10 patients with focal spasticity who are receiving botulinum toxin-A (BoNT-A) treatments after completing a 30-minute eCME.
Reflective questionnaire:
This short questionnaire completes the Patient Health Management program and allows healthcare specialists to reflect on the change in their clinical actions after the program.
Faculty
Heather Finlayson, MD, FRCPC, Dip. Sport Med, CSCN (EMG)
Colleen O’Connell, MD, FRCPC
Omar D. Khan, MD, FRCPC
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Describe the frequency and impact of symptom recurrence between botulinum toxin-A (BoNT-A) injections
- Discuss multi-modal treatment considerations in persons experiencing problematic spasticity while treated with BoNT-A
- Select appropriate treatment options for patients who experience disruptive symptoms towards the end of their treatment cycle